文献速递妇科

子宫内膜样子宫内膜癌总生存综合临床风险评分模型的开发与验证

Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2021-10-01

基于美国国家癌症数据库(NCDB)2004—2013年42,107例接受手术的子宫内膜样子宫内膜癌患者,采用Cox比例风险分析建立总生存风险评分模型,并在本机构(CCF)队列中内部验证。模型识别出6个风险组(评分0—30),每增加1分的风险比在NCDB与CCF队列分别为1.21(1.20-1.22,P<0.001)与1.18(1.12-1.25,P<0.001),c-index分别为0.80(0.79-0.81)与0.77(0.68-0.86)。

要点

  • 模型纳入年龄≥60岁、非裔美国人种族、Charlson-Deyo评分1或2+、较高分级、LVSI、肿瘤≥2cm及未行淋巴结清扫等预后因素。
  • 模型将患者分为6个风险组(评分0—30),并给出各组总生存估计。
  • 在IA期和IB期分别进行类似分析,辅助治疗对多数IB期患者生存有益,而IA期仅6个风险组中的1组获益。

核心结论

  • 报告了一个经过验证的子宫内膜样子宫内膜癌患者总生存综合风险评分模型。

研究设计与样本

  • 通过NCDB识别2004—2013年诊断的子宫内膜样子宫内膜癌患者,纳入已知LVSI状态且接受手术(伴或不伴辅助治疗)者。
  • 采用Cox比例风险分析识别总生存预后因素,按风险比赋值并计算风险评分,用递归 partitioning 分析(RPA)划分风险组。
  • 结果在本机构(CCF)患者队列中进行内部验证,计算风险评分并用Cox回归模型评估,计算Harrell c-index评估模型拟合。

主要发现

  • 研究期间349,404例子宫内膜样子宫内膜癌女性中,42,107例符合纳入标准。
  • 与更差总生存相关的因素包括年龄≥60岁、非裔美国人种族、Charlson-Deyo评分1或2+、较高分级、LVSI、肿瘤大小≥2 cm及未行淋巴结清扫。
  • 识别出6个风险组(评分0—30),并估计了每个风险组的总生存。
  • NCDB与CCF队列每1分风险评分增加的风险比分别为1.21(1.20-1.22,P<0.001)与1.18(1.12-1.25,P<0.001),c-index分别为0.80(0.79-0.81)与0.77(0.68-0.86)。
  • 在IA期和IB期进行类似分析;辅助治疗对多数IB期患者生存有益,而IA期仅6个风险组中的1组获益。

关键数值与推荐

  • 风险评分每增加1分的风险比:NCDB队列1.21(1.20-1.22,P<0.001),CCF队列1.18(1.12-1.25,P<0.001)。
  • 模型c-index:NCDB队列0.80(0.79-0.81),CCF队列0.77(0.68-0.86)。
  • 风险评分范围0—30,对应6个风险组。

临床怎么用

  • 该模型可用于子宫内膜样子宫内膜癌患者的总生存风险分层,辅助临床决策。
  • 辅助治疗对多数IB期患者生存有益,而IA期仅部分风险组获益,可结合风险评分个体化评估。

局限性

  • 模型仅在本机构队列中进行内部验证,未进行外部独立验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop and validate a comprehensive overall survival (OS) risk-scoring model in women with endometrioid endometrial cancer (EC). METHODS: Patients with EC diagnosed from 2004 to 2013 were identified through the National Cancer Database (NCDB). Patients with known lymphovascular space invasion (LVSI) status who were treated surgically (with or without adjuvant therapy) were included. Cox proportional hazards analysis was used to identify prognostic factors for OS. This model was used to assign points based on hazard ratios for risk factors and a risk score was obtained. Recursive partitioning analysis (RPA) was used to categorize patients into risk groups. Results were internally validated in a cohort of patients from our institution (CCF cohort). Risk scores were calculated and assessed in a Cox regression model, and Harrell's c-index was calculated to assess model fit. RESULTS: Among 349,404 women with EEC during the study period, 42,107 fulfilled inclusion criteria. Factors associated with worse OS were age ≥ 60, African American race, Charlson-Deyo score 1 or 2+, higher grade, LVSI, tumor size ≥2 cm, and no lymphadenectomy performed. Six risk groups were identified (scores 0-30) and OS estimated for each risk group. Risk score per 1-point increase in HR were comparable between NCDB and CCF cohorts (HR 1.21 (1.20-1.22 p < 0.001 vs 1.18 (1.12-1.25), p < 0.001), and c-index 0.80 (0.79-0.81) vs. 0.77 (0.68-0.86). Similar analysis was done in stage IA and IB. Adjuvant therapy had a beneficial effect on survival in the majority of stage IB patients, but only one of the six risk groups in stage IA EC. CONCLUSIONS: We report a comprehensive validated OS risk-scoring model for patients with.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. AlHilli MM, Rybicki L, Carr C, et al. Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma. Gynecol Oncol. 2021. PMID: 34607712. doi:10.1016/j.ygyno.2021.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。